Epidemiological impact of

Chlamydia Infections Epidemiology Models, Statistical NEISSERIA GONORRHOEAE

Journal

Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554

Informations de publication

Date de publication:
24 May 2024
Historique:
received: 27 12 2023
accepted: 14 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 24 5 2024
Statut: aheadofprint

Résumé

The impact of the systematic screening of We modelled NG and CT transmission using a site-specific deterministic compartmental model. We calibrated NG and CT prevalence at baseline using results from MSM enrolled in the Dat'AIDS cohort. The baseline scenario was based on 1 million MSM, 40 000 of whom were tested every 90 days and 960 000 every 200 days. Incidence rate ratios (IRRs) at steady state were simulated for NG, CT, NG and/or CT infections, for different combinations of tested sites, testing frequency and numbers of frequently tested patients. The observed prevalence rate was 11.0%, 10.5% and 19.1% for NG, CT and NG and/or CT infections. The baseline incidence rate was estimated at 138.2 per year per 100 individuals (/100PY), 86.8/100PY and 225.0/100PY for NG, CT and NG and/or CT infections. Systematically testing anal, pharyngeal and urethral sites at the same time reduced incidence by 14%, 23% and 18% (IRR: 0.86, 0.77 and 0.82) for NG, CT and NG and/or CT infections. Reducing the screening interval to 60 days in frequently tested patients reduced incidence by 20%, 29% and 24% (IRR: 0.80, 0.71 and 0.76) for NG, CT and NG and/or CT infections. Increasing the number of frequently tested patients to 200 000 reduced incidence by 29%, 40% and 33% (IRR: 0.71, 0.60 and 0.67) for NG, CT and NG and/or CT infections. No realistic scenario could decrease pathogens' incidence by more than 50%. To curb the epidemic of NG and CT in MSM, it would not only be necessary to drastically increase screening, but also to add other combined interventions.

Identifiants

pubmed: 38789265
pii: sextrans-2023-056103
doi: 10.1136/sextrans-2023-056103
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Julien Flaig (J)

EPIMOD, Lyon, France.

Laurent Hocqueloux (L)

Infectious Diseases, CHU d'Orléans, Orléans, France laurent.hocqueloux@chu-orleans.fr.

Romain Palich (R)

Department of Infectious Diseases, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Pitié Salpêtrière Hospital, Paris, France.

Lise Cuzin (L)

CHU de Martinique, Fort-de-France, Martinique.

Olivier Robineau (O)

CH Gustave Dron de Tourcoing, Tourcoing, France.

Pascal Pugliese (P)

Corevih, CHU de Nice, Côte d'Azur University, Nice, France.

Cyrille Delpierre (C)

CERPOP, Université Toulouse III-Paul Sabatier, Toulouse, France.

Nicolas Voirin (N)

EPIMOD, Lyon, France.

Laurent Cotte (L)

Infectious Diseases, Hopital de la Croix-Rousse, Lyon, France.

Classifications MeSH